The use of the PDE4 inhibitor roflumilast provides a novel therapeutic option that improves lung function in COPD patients, and preclinically has been shown to produce a variety of anti-inflammatory effects [21-23]. Here, PDE4A is linked to chronic obstructive pulmonary disease.